US10806X1028

CORRECTING and REPLACING — BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026 17:10 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In…

2 weeks ago

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026 10:30 ET  | Source: BridgeBio Pharma, Inc. - Preliminary unaudited Q4 and Full Year 2025 net Attruby® product…

4 weeks ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

September 06, 2025 14:30 ET  | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…

5 months ago